NO974899L - Analogifremgangsmåte for fremstilling av en terapeutisk aktiv aprotinin-analog - Google Patents

Analogifremgangsmåte for fremstilling av en terapeutisk aktiv aprotinin-analog

Info

Publication number
NO974899L
NO974899L NO974899A NO974899A NO974899L NO 974899 L NO974899 L NO 974899L NO 974899 A NO974899 A NO 974899A NO 974899 A NO974899 A NO 974899A NO 974899 L NO974899 L NO 974899L
Authority
NO
Norway
Prior art keywords
therapeutically active
preparing
analogous process
active aprotinin
aprotinin analog
Prior art date
Application number
NO974899A
Other languages
English (en)
Other versions
NO974899D0 (no
Inventor
Soeren Bjoern
Kjeld Norris
Fanny Norris
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26065137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO974899(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DK494189A external-priority patent/DK494189D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO974899L publication Critical patent/NO974899L/no
Publication of NO974899D0 publication Critical patent/NO974899D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Processing Of Solid Wastes (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Particle Accelerators (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det beskrives nye terapeutisk aktive aprotininanaloger med den generelle formel x4 aprotinin (1-58) hvor X4 representerer en N-cerminalutvidelse med en eller flere aminosyrer.
NO974899A 1989-03-03 1997-10-23 Analogifremgangsmåte for fremstilling av en terapeutisk aktiv aprotinin-analog NO974899D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK105489A DK105489D0 (da) 1989-03-03 1989-03-03 Polypeptid
DK494189A DK494189D0 (da) 1989-10-06 1989-10-06 Polypeptid
PCT/DK1990/000058 WO1990010075A1 (en) 1989-03-03 1990-03-01 Yeast processing system comprising a negatively charged amino acid adjacent to the processing site

Publications (2)

Publication Number Publication Date
NO974899L true NO974899L (no) 1997-10-23
NO974899D0 NO974899D0 (no) 1997-10-23

Family

ID=26065137

Family Applications (2)

Application Number Title Priority Date Filing Date
NO913427A NO304236B1 (no) 1989-03-03 1991-09-02 Polypeptid omfattende en sammensmelting av et signalpeptid, et lederpeptid og et heterologt protein eller polypeptid, DNA-konstruksjoner omfattende en DNA-sekvens som koder for polypeptidet samt gjµrstamme og vektor som kan uttrykke det
NO974899A NO974899D0 (no) 1989-03-03 1997-10-23 Analogifremgangsmåte for fremstilling av en terapeutisk aktiv aprotinin-analog

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO913427A NO304236B1 (no) 1989-03-03 1991-09-02 Polypeptid omfattende en sammensmelting av et signalpeptid, et lederpeptid og et heterologt protein eller polypeptid, DNA-konstruksjoner omfattende en DNA-sekvens som koder for polypeptidet samt gjµrstamme og vektor som kan uttrykke det

Country Status (23)

Country Link
US (3) US5395922A (no)
EP (1) EP0461165B2 (no)
JP (1) JP2609367B2 (no)
KR (1) KR970005928B1 (no)
AT (1) ATE110414T1 (no)
AU (1) AU624694B2 (no)
CA (1) CA2050336C (no)
CZ (1) CZ285239B6 (no)
DD (1) DD296965A5 (no)
DE (1) DE69011853T3 (no)
DK (2) DK105489D0 (no)
ES (1) ES2062514T5 (no)
FI (1) FI104985B (no)
HU (2) HU215538B (no)
IE (1) IE66469B1 (no)
IL (1) IL93609A (no)
NO (2) NO304236B1 (no)
NZ (1) NZ232742A (no)
PL (1) PL163532B1 (no)
RU (1) RU2194758C2 (no)
UA (1) UA27706C2 (no)
WO (1) WO1990010075A1 (no)
ZA (1) ZA901476B (no)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591603A (en) * 1987-08-28 1997-01-07 Novo Nordisk A/S Process for preparing aprotinin and aprotinin analogs in yeast cells
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
JPH04507341A (ja) * 1989-05-19 1992-12-24 バイオテクノロジー　リサーチ　アンド　ディヴェロプメント　コーポレーション ｉｎ　ｖｉｖｏ翻訳後修飾部位を有する融合タンパク質及び製造及び精製方法
GB9015825D0 (en) * 1990-07-18 1990-09-05 Ciba Geigy Ag In vitro processing of fusion proteins
DK300090D0 (da) * 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
GB9106185D0 (en) * 1991-03-22 1991-05-08 Wellcome Found Biological control agents
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FI92601C (fi) * 1992-03-11 1994-12-12 Marja Makarow Menetelmä hyötyproteiinien erittämiseksi hiivoista
US5521086A (en) * 1993-09-16 1996-05-28 Cephalon, Inc. Secretion sequence for the production of a heterologous protein in yeast
DE4417353A1 (de) * 1994-05-18 1996-01-25 Bayer Ag Verfahren zur Herstellung von rekombinantem Aprotinin und rekombinanten Aprotinin Varianten mit der natürlichen N-terminlaen Sequenz
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
IL114160A (en) * 1994-06-17 2006-12-31 Novo Nordisk As Dna constructs encoding heterologous proteins and processes for the heterologous protein production in yeast
US5861267A (en) * 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
ZA9610456B (en) * 1995-12-20 1997-06-20 Novo Nordisk As N-terminally extended proteins expressed in yeast
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
DE19629982A1 (de) 1996-07-25 1998-01-29 Bayer Ag Aprotinin-Varianten mit verbesserten Eigenschaften
EP1935901A1 (en) 1996-12-13 2008-06-25 Novartis Vaccines and Diagnostics, Inc. Analysis and separation of platelet-derived growth factor proteins
ES2258797T3 (es) * 1996-12-20 2006-09-01 Novo Nordisk A/S Proteinas con extension n-terminal expresadas en la levadura.
EP0954589A1 (en) * 1997-01-24 1999-11-10 Novo Nordisk A/S Synthetic leader peptide sequences
US6046000A (en) * 1997-11-07 2000-04-04 Millennium Biotherapeutics, Inc. Method for identifying genes encoding signal sequences
AU2149899A (en) 1998-01-23 1999-08-09 Novo Nordisk A/S Process for making desired polypeptides in yeast
JP4795599B2 (ja) 1999-12-29 2011-10-19 ノボ ノルディスク アクティーゼルスカブ 酵母において改良された発酵収率を有するインスリン前駆体及びインスリン前駆体類似体の製造方法
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) * 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2004024885A2 (en) 2002-09-13 2004-03-25 Cornell Research Foundation, Inc. Using mutations to improve aspergillus phytases
EP1687428A1 (en) 2003-11-14 2006-08-09 Novo Nordisk A/S Processes for making acylated insulin
EP1692168B1 (en) 2003-12-03 2011-07-20 Novo Nordisk A/S Single-chain insulin
CN102660614A (zh) 2005-08-16 2012-09-12 诺沃-诺迪斯克有限公司 制备成熟胰岛素多肽的方法
DE602007009496D1 (de) 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
US8198046B2 (en) 2006-07-11 2012-06-12 Danisco Us Inc. KEX2 cleavage regions of recombinant fusion proteins
US20080026376A1 (en) 2006-07-11 2008-01-31 Huaming Wang KEX2 cleavage regions of recombinant fusion proteins
RU2524150C2 (ru) 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
EP2069502B1 (en) 2006-09-27 2014-02-26 Novo Nordisk A/S Method for making maturated insulin polypeptides
EP2084179B1 (en) 2006-11-22 2013-05-22 Novo Nordisk A/S Method for making activated carboxypeptidases
JP5688969B2 (ja) 2007-07-16 2015-03-25 ノボ・ノルデイスク・エー／エス プロテアーゼに対して安定しているペグ化インスリンアナログ
JP5710253B2 (ja) 2007-08-13 2015-04-30 ノボ・ノルデイスク・エー／エス 速効型インスリンアナログ
JP5721432B2 (ja) 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
US9150633B2 (en) 2007-08-15 2015-10-06 Novo Nordisk A/S Insulin analogues with an acyl and alkylene glycol moiety
US8501449B2 (en) 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
CN102065903B (zh) 2008-04-01 2015-02-18 诺沃-诺迪斯克有限公司 胰岛素清蛋白缀合物
MY161552A (en) * 2009-03-12 2017-04-28 Bigtec Private Ltd A polynucleotide and polypeptide sequence and methods thereof
KR101775000B1 (ko) 2009-06-26 2017-09-04 노보 노르디스크 에이/에스 인슐린, 니코틴아미드 및 아미노산을 포함하는 제제
ES2550761T3 (es) 2009-11-25 2015-11-12 Novo Nordisk A/S Método para producción de polipéptidos
ES2543634T3 (es) 2010-01-22 2015-08-20 Novo Nordisk A/S Proceso para preparación de FGF-21 con grado de O-glicosilación bajo
WO2011161083A1 (en) 2010-06-23 2011-12-29 Novo Nordisk A/S Human insulin containing additional disulfide bonds
JP5973427B2 (ja) 2010-06-23 2016-08-23 ノヴォ ノルディスク アー／エス 追加のジスルフィド結合を含有するインスリン類似体
KR20130036290A (ko) 2010-06-23 2013-04-11 노보 노르디스크 에이/에스 추가 이황화 결합을 함유하는 인슐린 유도체
KR20140030125A (ko) 2010-12-14 2014-03-11 노보 노르디스크 에이/에스 인슐린, 니코틴아미드 및 아미노산을 포함하는 제제
WO2012080320A1 (en) 2010-12-14 2012-06-21 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
CN103596584B (zh) 2011-06-15 2016-12-14 诺沃—诺迪斯克有限公司 多取代的胰岛素
RU2460795C1 (ru) * 2011-07-06 2012-09-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика") Способ микробиологического синтеза секретируемого соматотропина человека и штамм дрожжей saccharomyces cerevisiae - продуцент секретируемого соматотропина человека
WO2013186138A1 (en) 2012-06-14 2013-12-19 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and arginine
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
CN103254277B (zh) * 2013-05-03 2017-02-08 南京工业大学 强分泌性信号肽增强小肽模序及其应用
JP2016521701A (ja) 2013-06-07 2016-07-25 ノヴォ ノルディスク アー／エス 成熟インスリンポリペプチドを作製するための方法
PL233560B1 (pl) 2014-12-05 2019-10-31 Mabion Spolka Akcyjna Sposób otrzymywania insuliny lub analogu insuliny z prekursora rekombinowanego białka
US10562951B2 (en) 2015-03-10 2020-02-18 Merck Sharp & Dohme Corp. Process for preparing recombinant insulin using microfiltration
ES2784603T3 (es) 2015-06-02 2020-09-29 Novo Nordisk As Insulinas con extensiones recombinantes polares
CN108368163A (zh) 2015-08-25 2018-08-03 诺和诺德股份有限公司 新型胰岛素衍生物及其医学用途
ES2908373T3 (es) 2015-08-25 2022-04-28 Novo Nordisk As Nuevos derivados de insulina y los usos médicos de los mismos
US20190010206A1 (en) 2015-08-25 2019-01-10 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
KR102043067B1 (ko) * 2017-08-08 2019-11-11 엘지전자 주식회사 차량용 사이드 미러 및 차량
US10919949B2 (en) 2017-08-17 2021-02-16 Novo Nordisk A/S Acylated insulin analogues and uses thereof
DK4073097T3 (da) 2019-12-11 2024-08-19 Novo Nordisk As Nye insulinanaloger og anvendelser heraf
WO2023144240A1 (en) 2022-01-26 2023-08-03 Novo Nordisk Research Centre Oxford Limited Glucose sensitive insulin derivatives and uses thereof
DE202024104234U1 (de) 2024-07-26 2024-12-18 Australian Geekkit Health Pty Ltd Peptid-Struktur-Partikel mit Signalübertragung

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5712580A (en) * 1979-04-05 1980-10-09 James Joseph Connell Engine charging and scavenging
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
JPS60501140A (ja) * 1983-04-22 1985-07-25 アムジエン 酵母による外因性ポリペプチドの分泌
US4588684A (en) * 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
DK58285D0 (da) * 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
EP0195680A3 (en) * 1985-03-21 1987-06-10 Immunex Corporation The synthesis of protein with an identification peptide
JPS6236183A (ja) * 1985-06-20 1987-02-17 ザ・サルク・インステイチユ−ト・バイオテクノロジ−／インダストリアル・アソシエイツ・インコ−ポレ−テツド サツカロミセス・セレビシエからのポリペプチドの発現および分泌
MC1834A1 (fr) * 1986-07-10 1988-06-03 Transgene Sa Bloc fonctionnel d'adn et plasmide codant pour l'hirudine,levure transformee,procede de preparation de l'hirudine,hirudine obtenue et son utilisation
US4987070A (en) * 1987-03-04 1991-01-22 Suntory Limited Use of a 97 amino acid leader sequence from the E. coli B-galactosidase gene for the production of hanp and hptc as fusion proteins
EP0371041A1 (en) * 1987-06-24 1990-06-06 Novo Nordisk A/S A process for preparing a protein or polypeptide, a dna sequence coding for the polypeptide, a microorganism containing the dna sequence as well as the polypeptide and its use as a pharmaceutical preparation
DK450187D0 (da) * 1987-08-28 1987-08-28 Novo Industri As Fremgangsmaade til fremstilling af proteiner
DK463887D0 (da) * 1987-09-07 1987-09-07 Novo Industri As Gaerleader
JPH01240191A (ja) * 1988-02-16 1989-09-25 Green Cross Corp:The 酵母で機能する新規シグナルペプチドおよびこれを用いた異種蛋白質の分泌発現
DK336188D0 (da) * 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
EP0387319B1 (en) * 1988-07-23 1996-03-06 Delta Biotechnology Limited Secretory leader sequences
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid

Also Published As

Publication number Publication date
ATE110414T1 (de) 1994-09-15
WO1990010075A1 (en) 1990-09-07
US5510249A (en) 1996-04-23
FI104985B (fi) 2000-05-15
KR970005928B1 (ko) 1997-04-22
DK0461165T3 (da) 1994-11-21
EP0461165A1 (en) 1991-12-18
IL93609A (en) 2001-11-25
HU902376D0 (en) 1991-11-28
NO913427D0 (no) 1991-09-02
IL93609A0 (en) 1990-12-23
IE66469B1 (en) 1995-12-27
RU2194758C2 (ru) 2002-12-20
NZ232742A (en) 1991-10-25
HU211600A9 (en) 1995-12-28
NO304236B1 (no) 1998-11-16
US5395922A (en) 1995-03-07
HU215538B (hu) 1999-01-28
AU5261290A (en) 1990-09-26
IE900749L (en) 1990-09-03
DD296965A5 (de) 1991-12-19
UA27706C2 (uk) 2000-10-16
DE69011853T3 (de) 1998-06-25
JPH04504846A (ja) 1992-08-27
ZA901476B (en) 1990-11-28
CA2050336A1 (en) 1990-09-04
CZ285239B6 (cs) 1999-06-16
DE69011853D1 (de) 1994-09-29
HUT58370A (en) 1992-02-28
DE69011853T2 (de) 1994-12-15
AU624694B2 (en) 1992-06-18
EP0461165B1 (en) 1994-08-24
ES2062514T3 (es) 1994-12-16
JP2609367B2 (ja) 1997-05-14
PL163532B1 (pl) 1994-04-29
CA2050336C (en) 2000-01-18
CZ103990A3 (cs) 1999-03-17
US5514585A (en) 1996-05-07
NO913427L (no) 1991-11-01
FI914125A0 (fi) 1991-09-02
DK105489D0 (da) 1989-03-03
KR920701452A (ko) 1992-08-11
NO974899D0 (no) 1997-10-23
ES2062514T5 (es) 1998-06-01
EP0461165B2 (en) 1998-03-25

Similar Documents

Publication Publication Date Title
NO974899L (no) Analogifremgangsmåte for fremstilling av en terapeutisk aktiv aprotinin-analog
FI96861C (fi) Menetelmä terapeuttisesti aktiivisten substituoitujen indolyylipyrrolijohdannaisten valmistamiseksi
NO175371C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive aminosyrederivater
NO167202C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive (1h-imidazol-1-ylmetyl)-substituerte benzimidazolderivater.
FI894477A7 (fi) Menetelmä terapeuttisesti aktiivisten 7-substituoitujen 3,5-dihydroksihept-6-yynihappojen ja niiden johdannaisten valmistamiseksi ja välituotteina käyttökelpoiset yhdisteet
NO167924C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive thymopentinanaloger
NO175100C (no) Analogifremgangsmåte til fremstilling av terapeutisk aktive 4(3H)-pteridinoner
NO175258C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 7-oksabicykloheptyl-substituerte heterocyklisk amidprostaglandinanaloger
NO903941D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive diazepinon-derivater.
FI893883A7 (fi) Menetelmä terapeuttisesti aktiivisten 7-tetrahydronaftyridiini-6-fluori-1,4-dihydro-4-oksokinoliini-3-karboksyylihappojen valmistamiseksi
NO173503C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tetrahydroimidayo (1,4) benzodiazepin-2-tioner
FI890841A7 (fi) Menetelmä uusien terapeuttisesti aktiivisten substituoitujen 7-hydroksi-2,3,4,5-tetrahydro-1H-3-bentsatsepiinien karbamiinihappoestereiden valmistamiseksi
NO177141C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive aminosyreantagonister
NO169963C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive, substituerte 3,4-dihydro-2h-benzopyraner
FI871087A7 (fi) Menetelmä terapeuttisesti aktiivisten 1,2,3,4-tetrahydro-3-karbamoyyli-2-tiokso/okso-5-pyrimidiinikarboksyylihappojohdannaisten valmistamiseksi
NO177500C (no) Fremgangsmåte til fremstilling av en terapeutisk aktiv hirudinvariant
NO155244C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-substituert-1,2-dihydro-3h-pyrrolo-(1,2-a)-pyrrol-1-carboxylsyrer fra deres tilsvarende nitriler.
NO882239D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive cykliske peptider.
NO863373D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminosyre derivater.
FI884660A0 (fi) Menetelmä terapeuttisesti aktiivisten 2,2-dimetyylikromeenijohdannaisten valmistamiseksi
IT7950629A0 (it) Procedimento per la preparazione di ossido di zirconio a partire da zirconato di calcio tecnico
NO173607C (no) Analogifremgangsmaate for fremstilling av nye terapeutisk aktive tienotriazolo-diazepin-derivater
ES2058928T3 (es) Peptidos que contienen diamino-glicoles como estados memeticos de transicion.
FI853648A7 (fi) Menetelmä farmaseuttisesti aktiivisten 4,5-dihydro-4-okso-2-/ (2-trans-fenyylisyklopropyyli)amino/ -3-furaanikarboksyylihappojen ja niiden johdannaisten valmistamiseksi.
FI882002L (fi) Menetelmä terapeuttisesti aktiivisten fenyylipiperidiinijohdannaisten valmistamiseksi